NYSEAMERICAN:LCTX Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis $0.84 -0.04 (-4.57%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.83▼$0.8950-Day Range N/A52-Week Range$0.77▼$1.61Volume376,589 shsAverage Volume873,955 shsMarket Capitalization$157.87 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Lineage Cell Therapeutics alerts: Email Address Lineage Cell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside577.8% Upside$5.67 Price TargetShort InterestBearish8.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 3 Articles This WeekInsider TradingAcquiring Shares$9,345 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.12) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.32 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLineage Cell Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Lineage Cell Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.21% of the outstanding shares of Lineage Cell Therapeutics have been sold short.Short Interest Ratio / Days to CoverLineage Cell Therapeutics has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.Change versus previous monthShort interest in Lineage Cell Therapeutics has recently increased by 6.52%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLineage Cell Therapeutics does not currently pay a dividend.Dividend GrowthLineage Cell Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LCTX. Previous Next 2.0 News and Social Media Coverage News SentimentLineage Cell Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lineage Cell Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for LCTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lineage Cell Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,345.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders28.10% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lineage Cell Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.12) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lineage Cell Therapeutics is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lineage Cell Therapeutics is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLineage Cell Therapeutics has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX)Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.Read More LCTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LCTX Stock News HeadlinesSeptember 4 at 6:15 AM | americanbankingnews.comLineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Short Interest UpdateAugust 21, 2024 | msn.comCraig-Hallum Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy RecommendationSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lineage Cell Therapeutics Amid Strategic Partnerships and Pipeline ProgressAugust 13, 2024 | finance.yahoo.comLineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 10, 2024 | markets.businessinsider.comLineage Cell Therapeutics: A Buy Rating Amidst Financial Stability and Promising Clinical ProgressAugust 10, 2024 | seekingalpha.comLineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call TranscriptJuly 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lineage Cell Therapeutics on Promising OpRegen Trials and Strategic Roche PartnershipSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…July 23, 2024 | finance.yahoo.comLineage Cell Therapeutics, Inc. (LCTX)July 22, 2024 | money.usnews.comArtiva Biotherapeutics IncMay 30, 2024 | businesswire.comLineage to Present at 2024 BIO International ConventionMay 26, 2024 | barrons.comLineage Cell Therapeutics Inc.May 21, 2024 | finance.yahoo.comLineage Announces Updates to 2nd Annual Spinal Cord Injury Investor SymposiumMay 14, 2024 | markets.businessinsider.comBuy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid FinancialsMay 10, 2024 | finance.yahoo.comQ1 2024 Lineage Cell Therapeutics Inc Earnings CallMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue DeclinesMay 10, 2024 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2024 Earnings Call TranscriptSee More Headlines Receive LCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:LCTX CUSIPN/A CIKN/A Webwww.lineagecell.com Phone(442) 287-8963Fax510-521-3389Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+577.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,490,000.00 Net Margins-391.00% Pretax Margin-391.25% Return on Equity-36.30% Return on Assets-23.12% Debt Debt-to-Equity RatioN/A Current Ratio2.64 Quick Ratio2.64 Sales & Book Value Annual Sales$8.94 million Price / Sales17.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book2.39Miscellaneous Outstanding Shares188,840,000Free Float135,746,000Market Cap$157.87 million OptionableNot Optionable Beta1.29 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Brian M. Culley M.A. (Age 53)M.B.A., CEO, President & Director Comp: $986.7kMs. Jill Ann Howe (Age 47)CFO & Principal Financial and Accounting Officer Comp: $587.4kMr. George A. Samuel III (Age 43)J.D., General Counsel & Company Secretary Comp: $554.51kIoana C. HoneDirector of Investor RelationsDr. Charlotte Hubbert Ph.D.Vice President of Corporate DevelopmentMs. Brandi L. Roberts CPA (Age 50)M.B.A., Consultant Comp: $407.45kMr. William Annett MBA (Age 70)President & CEO of OncoCyte Corporation Comp: $53.2kDr. Rami Skaliter Ph.D. (Age 66)Chief Executive Officer of Cell Cure Neurosciences Ms. Alexandra HernandezSenior Director of Finance & ControllerDr. Harold D. Waitz (Age 82)Vice President of Regulatory Affairs & Quality Control Comp: $90kMore ExecutivesKey CompetitorsHumacyteNASDAQ:HUMAAstria TherapeuticsNASDAQ:ATXSMereo BioPharma GroupNASDAQ:MREOY-mAbs TherapeuticsNASDAQ:YMABiTeos TherapeuticsNASDAQ:ITOSView All CompetitorsInsiders & InstitutionsLogos Global Management LPSold 1,550,000 shares on 8/27/2024Ownership: 2.489%Jill Ann HoweBought 10,500 shares on 8/16/2024Total: $9,345.00 ($0.89/share)Logos Global Management LPSold 1,550,000 shares on 8/14/2024Ownership: 2.489%Raffles Associates LPBought 1,147,800 shares on 8/14/2024Ownership: 2.308%XTX Topco LtdBought 61,515 shares on 8/12/2024Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions LCTX Stock Analysis - Frequently Asked Questions How have LCTX shares performed this year? Lineage Cell Therapeutics' stock was trading at $1.09 at the beginning of the year. Since then, LCTX shares have decreased by 23.3% and is now trading at $0.8360. View the best growth stocks for 2024 here. How were Lineage Cell Therapeutics' earnings last quarter? Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) released its earnings results on Thursday, August, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The business earned $1.41 million during the quarter, compared to analyst estimates of $1.28 million. Lineage Cell Therapeutics had a negative net margin of 391.00% and a negative trailing twelve-month return on equity of 36.30%. Who are Lineage Cell Therapeutics' major shareholders? Lineage Cell Therapeutics' top institutional shareholders include Logos Global Management LP (2.49%), Logos Global Management LP (2.49%), Raffles Associates LP (2.31%) and Renaissance Technologies LLC (0.31%). Insiders that own company stock include Broadwood Partners, LP, Don M Bailey, Brian M Culley, Jill Ann Howe, Gary S Hogge, Dipti Amin and Michael H Mulroy. View institutional ownership trends. How do I buy shares of Lineage Cell Therapeutics? Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lineage Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and CNBX Pharmaceuticals (CNBX). This page (NYSEAMERICAN:LCTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LCTX Stock Alerts